Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

F. Blanco,R. Möricke,E. Dokoupilová,C. Codding,J. Neal,M. Andersson,Susanne Rohrer,H. Richards
DOI: https://doi.org/10.1002/art.40070
2017-06-01
Arthritis & Rheumatology
Abstract:To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to or intolerance of tumor necrosis factor (TNF) inhibitors.
What problem does this paper attempt to address?